# Scalp Cooling in MBC

Source: https://onco.cc/trials/nct04986579/  
OnCo record `nct04986579` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Scalp cooling in Breast cancer, run by Dana-Farber Cancer Institute, now recruiting.

## Summary

Scalp Cooling in MBC is a phase 2 interventional study registered as NCT04986579 by Dana-Farber Cancer Institute, with 120 participants planned, started 2021-10-07 and due to reach its primary completion in 2028-06-01. Interventions recorded: Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan. Conditions recorded: Metastatic Breast Cancer, Chemotherapy-induced Alopecia.

Linked to the technology Scalp cooling because the registry names it ("scalp cooling") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04986579
- Phase: 2
- Setting: Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT04986579: https://clinicaltrials.gov/study/NCT04986579

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)

---
JSON: https://onco.cc/api/v1/entities/nct04986579.json